Acurx Pharmaceuticals LLC (NASDAQ:ACXP) — Market Cap & Net Worth
Market Cap & Net Worth: Acurx Pharmaceuticals LLC (ACXP)
Acurx Pharmaceuticals LLC (NASDAQ:ACXP) has a market capitalization of $4.40 Million ($4.40 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28810 globally and #5840 in its home market, demonstrating a -4.35% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Acurx Pharmaceuticals LLC's stock price $1.54 by its total outstanding shares 2855025 (2.86 Million). Review debt load of Acurx Pharmaceuticals LLC to assess the company's total debt and financial obligations.
Acurx Pharmaceuticals LLC Market Cap History: 2021 to 2026
Acurx Pharmaceuticals LLC's market capitalization history from 2021 to 2026. Data shows change from $12.34 Million to $4.40 Million (-27.97% CAGR).
Index Memberships
Acurx Pharmaceuticals LLC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #850 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2705 of 3165 |
Weight: Acurx Pharmaceuticals LLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Acurx Pharmaceuticals LLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Acurx Pharmaceuticals LLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ACXP by Market Capitalization
Companies near Acurx Pharmaceuticals LLC in the global market cap rankings as of June 18, 2026.
Key companies related to Acurx Pharmaceuticals LLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Acurx Pharmaceuticals LLC Historical Marketcap From 2021 to 2026
Between 2021 and today, Acurx Pharmaceuticals LLC's market cap moved from $12.34 Million to $ 4.40 Million, with a yearly change of -27.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.40 Million | -38.15% |
| 2025 | $7.11 Million | +205.90% |
| 2024 | $2.32 Million | -78.75% |
| 2023 | $10.93 Million | -3.77% |
| 2022 | $11.36 Million | -7.89% |
| 2021 | $12.34 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Acurx Pharmaceuticals LLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.40 Million USD |
| MoneyControl | $4.40 Million USD |
| MarketWatch | $4.40 Million USD |
| marketcap.company | $4.40 Million USD |
| Reuters | $4.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potenti… Read more